1
|
Platelet indices in patients with acute appendicitis: a systematic review with meta-analysis. Updates Surg 2021; 73:1327-1341. [PMID: 33439467 DOI: 10.1007/s13304-020-00928-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 11/11/2020] [Indexed: 02/07/2023]
Abstract
Correlation between blood inflammatory parameters and acute appendicitis (AA) remains controversial. This meta-analysis aims to evaluate whether platelet (PLT) indices including mean platelet volume (MPV), PLT count, and platelet distribution width (PDW) are associated with AA. Pubmed, Embase, and Cochrane Library databases were searched for observational studies published from inception through April 2020 by two independent investigators. Studies reporting associations between platelet indices and AA were selected for inclusion. Standardized mean difference (SMD) and 95% confidence interval (CI) were estimated for continuous outcomes using a DerSimonian-Laird random-effects model. Of 842 records identified, 17 studies with a total of 6793 subjects met our inclusion criteria. Meta-analysis indicated that compared with those in healthy controls, significant decrease in MPV levels was observed in subjects with AA (SMD - 0.34; 95% CI - 0.56 to - 0.12; P = 0.003). Subgroup analyses represented a significant reduction of MPV levels in patients aged ≥ 30 years and non-complicated/non-perforated AA. Due to the small number of studies and patients included in each subgroup, these subgroup analyses need to be interpreted with caution. However, none of the levels of PLT (SMD - 0.13; 95% CI - 0.28-0.012; P = 0.071) or PDW (SMD 0.30; 95% CI - 0.22-0.83; P = 0.257) was seen decrease or increase in subjects with AA. This meta-analysis indicates a significant decrease in MPV levels in patients with AA, which makes MPV have the potential of serving as a biomarker for AA. The associations of other PLT indices with AA need to be further examined.
Collapse
|
2
|
Eroğlu A, Ozcan H, Eryavuz Y, Kocağlu H, Demirci S, Aytac SK. Deep Venous Thrombosis of the Extremity Diagnosed by Color Doppler Ultrasonography after Isolated Limb Perfusion. TUMORI JOURNAL 2018; 87:187-90. [PMID: 11504375 DOI: 10.1177/030089160108700314] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aim Isolated limb perfusion (ILP) is used to treat locally advanced sarcoma and melanoma of the extremities. ILP is associated with a 1.7% to 10% incidence of deep venous thrombosis (DVT). The aim of the study was to examine the effect of ILP on the peripheral venous system and to evaluate the diagnostic accuracy of color Doppler ultrasonography (US). Methods A total of 26 patients with locally advanced sarcoma or melanoma of the extremities received a total of 38 ILP. The patients were evaluated preoperatively and postoperatively by color Doppler US as a noninvasive venous measurement. We used a color Doppler US system (SSA-270A, Toshiba) with a 7.5-MHz linear transducer for gray-scale imaging and a 5-MHz vascular transducer for color Doppler imaging. Results Seventeen patients underwent single ILP while the others were treated with multiple ILPs. Color Doppler US showed a reflux flow in three (7.9%) patients and DVT occurred subsequently in these patients. Conclusions Color Doppler US is a noninvasive and clinically useful diagnostic technique in the diagnosis of extremity DVT. We recommend anticoagulant therapy in patients with reflux on ultrasonographic examination.
Collapse
Affiliation(s)
- A Eroğlu
- Department of Surgical Oncology, Ankara University Medical School, Turkey.
| | | | | | | | | | | |
Collapse
|
3
|
Ariyan S. Regional isolated perfusion of extremities for melanoma: now a 26-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg 2003; 111:1257-61. [PMID: 12621200 DOI: 10.1097/01.prs.0000046041.63021.44] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Stephan Ariyan
- Melanoma Unit of the Yale Cancer Center, Department of Surgery, Yale University School of Medicine, 60 Temple Street, New Haven, CT 06510, USA.
| |
Collapse
|
4
|
Ariyan S, Poo WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 1998. [DOI: 10.1016/s0039-6060(98)70188-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Vrouenraets BC, Kroon BB, Klaase JM, Bonfrer JM, Nieweg OE, van Slooten GW, van Dongen JA. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol 1997; 4:88-94. [PMID: 8985522 DOI: 10.1007/bf02316815] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Severe limb toxicity following isolated limb perfusion (ILP) can lead to compartmental compression syndrome and severe rhabdomyolysis, occasionally necessitating amputation of the affected limb. We determined whether laboratory tests for muscle damage and inflammation could predict impending limb toxicity. METHODS All 184 consecutive ILPs performed in our institute from 1988 to 1994 were included in this study. Creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (ASAT) and white blood cell (WBC) counts were determined on post-ILP days 1-4, 6, 8, and 15. RESULTS "Late peak" CK patterns, characterised by a peak on or after the 5th post-perfusion day, were strongly associated with severe limb toxicity (p < 0.001). Severe toxicity did develop in 40% of the limbs when CK values exceeded 1000 IU/L on the 2nd to 5th post-ILP day (p < 0.001). There was a correlation between the peak CK and the individual grades of toxicity (r = 0.6, p < 0.001). Serum LDH and ASAT values peaked 2.9 and 3.4 days after the CK peak respectively. Severe limb toxicity was statistically significantly associated with higher WBC counts from the 2nd post-ILP day onwards. CONCLUSIONS CK values exceeding 1000 IU/L after the 1st and WBC counts increasing after the 2nd post-ILP day could be predictors of impending limb toxicity. These patients should be observed closely for signs of compartmental compression syndrome and severe rhabdomyolysis.
Collapse
Affiliation(s)
- B C Vrouenraets
- Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis), Amsterdam, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
6
|
Didolkar MS, Jackson AJ, Lesko LJ, Fitzpatrick JL, Buda BS, Johnston GS, Zech LA. Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma. J Surg Oncol 1996; 63:148-58. [PMID: 8944058 DOI: 10.1002/(sici)1096-9098(199611)63:3<148::aid-jso4>3.0.co;2-d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND The pharmacokinetics of dacarbazine (DTIC), which has been shown to be an effective therapeutic agent against metastatic melanoma, has not been extensively studied. However, to improve the clinical use of the drug, more information on the kinetics is required. METHODS A pharmacokinetic study was undertaken in six patients with melanoma of an extremity who were undergoing hyperthermic isolation perfusion with DTIC in order to understand better its clinical pharmacokinetics. Plasma was sampled from the arterial and venous lines of an extracorporeal pump during the perfusion with the systemic vein and urine sampled postperfusion. Samples were analyzed for DTIC. 2-azahypoxanthine (2-AZA), and aminoimidazole carboxamide (AIC). 99(m)Tc (Technetium) human serum albumin (HSA) was used in the perfusion circuit to monitor the crossover of the perfusate into the systemic circulation during the procedure. The data were analyzed using a compartmental model of sampled body compartments incorporating the isolated extremity. RESULTS High tissue DTIC levels were maintained throughout the perfusion, whereas in the systemic circulation, plasma DTIC concentrations, when observed, were 40-100-fold less than those in the perfusate. Almost 70% of the DTIC administered was not recovered in the perfusate after the washout of the extremity. CONCLUSIONS High levels of DTIC can be maintained in an extremity (i.e., arm or leg) during perfusion.
Collapse
Affiliation(s)
- M S Didolkar
- Department of Surgery, Sinai Hospital, Baltimore, MD 21215, USA
| | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
The technique of isolated limb perfusion for treatment of extremity melanoma has been used in the United States for almost 40 years. The treatment is based upon the ability to isolate the circulation of the afflicted extremity from the systemic circulation, thereby allowing dose-intensive delivery of anti-cancer agents to the limb while eliminating systemic exposure and toxicity. A number of agents have been used in ILP, however, the bulk of clinical experience has been with the alkylating agent melphalan, typically used under conditions of mild hyperthermia. Despite considerable clinical experience, there has been a lack of agreement about the role of ILP in the prophylaxis against or the treatment of recurrent extremity melanoma. Recently there has been renewed interest in the use of ILP based upon the very promising results using a combination of tumor necrosis factor, melphalan, and interferon-gamma which have produced complete response (CR) rates of almost 90%. The utility of this regimen in extremity melanoma is actively being evaluated by clinical trials in the United States and Europe.
Collapse
Affiliation(s)
- H R Alexander
- Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892-1502, USA
| | | | | |
Collapse
|
8
|
Sonneveld EJ, Vrouenraets BC, van Geel BN, Eggermont AM, Klaase JM, Nieweg OE, van Dongen JA, Kroon BB. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 1996; 22:521-7. [PMID: 8903497 DOI: 10.1016/s0748-7983(96)93085-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Systemic exposure to melphalan is minimized during isolated limb perfusion (ILP) by isolating a limb from the rest of the body. Consequently, there should be no toxicity to vital organs. At present systemic toxicity after ILP has not been studied in detail. Therefore, the incidence, nature and risk factors of systemic toxicity was retrospectively studied in 368 patients who underwent a single ILP with melphalan between 1978-1990. Some form of systemic toxicity occurred in 98 patients (27%). Nausea and vomiting after the 1st post-ILP day was seen in 73 patients (20%), and in seven (2%) treatment was required. Bone marrow depression was encountered in seven patients (2%): WHO grade II in five, and grade III in two. Miscellaneous systemic side-effects, including fever and minimal scalp hair loss, occurred in 19 patients (5%). Leakage from the isolated circuit to the systemic circulation was measured with radioactive tracers. Mean cumulative leakage during ILP was 0.9%. Systemic toxicity was not increased in patients with leakage greater than 1% or 5%. Female sex was associated with an increased incidence of systemic toxicity (P<0.05). Age over 60 years (P<0.05) and more severe acute regional toxicity (P<0.05) were correlated with nausea and vomiting. The miscellaneous systemic side-effects were more frequently encountered in women than in men (P<0.05). In conclusion, systemic toxicity was rarely severe, with nausea and vomiting being the most frequently encountered side-effects. Age over 60 years, female sex and more severe acute regional toxic reactions were correlated with an increased incidence of systemic side-effects. Systemic leakage during ILP was not associated with toxicity, probably due to the low incidence of significant leakage.
Collapse
Affiliation(s)
- E J Sonneveld
- Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? Eur J Cancer 1996. [DOI: 10.1016/0959-8049(96)00123-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
10
|
Fletcher WS, Pommier RF, Woltering EA, Mueller CR, Ash KO, Small KA. Pharmacokinetics and results of dose escalation in cis-platin hyperthermic isolation limb perfusion. Ann Surg Oncol 1994; 1:236-43. [PMID: 7842294 DOI: 10.1007/bf02303529] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND We analyzed prospectively collected data on 145 cis-platin hyperthermic isolation limb perfusion (HILPs) for melanoma and soft-tissue sarcoma to determine the pharmacokinetics and maximum tolerable dose of cis-platin. There were 70 melanoma and 75 sarcoma patients. Dosages ranged from 26 to 265 mg/m2. Perfusate and systemic cis-platin levels were measured in patients perfused at doses of 190-200 mg/m2. Tissue levels were measured in patients perfused at 123-209 mg/m2. METHODS Cis-platin HILP was well tolerated up to doses of 250 mg/m2 for lower extremities. Higher doses produced toxicities of rhabdomyolysis, myoglobinuria, hyponatremia, and neuropathy. Systemic levels of cis-platin were equivalent to those of routine intravenous administration, while perfusate levels were 33 times higher. Tissue levels of cis-platin were five to six times higher than effective intravenous levels. RESULTS Six melanoma patients have developed local recurrences. All were perfused at doses < 120 mg/m2. However, regional nodal recurrences have occurred in six other patients perfused at doses < or = 200 mg/m2. Four sarcomas have recurred locally, but three of them were present at the time of perfusion. CONCLUSIONS We conclude that 250 mg/m2 is the maximum tolerable dose of cis-platin for lower-extremity HILPs. Neoadjuvant cis-platin HILP may improve local control rates for sarcomas. However, no tolerable dose of cis-platin provides control of nodal metastases from melanoma.
Collapse
Affiliation(s)
- W S Fletcher
- Department of Surgery, Oregon Health Sciences University, Portland 97201-3098
| | | | | | | | | | | |
Collapse
|
11
|
Abstract
For over 35 years, various centres throughout the world have surgically perfused extremities afflicted with various stages of melanoma. Throughout these years the true effectiveness of this invasive technique has remained controversial. Herein, an attempt has been made to critically survey this literature, with emphasis on reports from the past few years, to ascertain what role limb perfusion may play in the 1990s.
Collapse
Affiliation(s)
- G J Bowers
- Department of Surgery, University of Florida Health Science Center/Jacksonville, Florida 32209
| | | |
Collapse
|
12
|
Hoekstra HJ, Schraffordt Koops H, de Vries LG, van Weerden TW, Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993; 72:1224-9. [PMID: 8393368 DOI: 10.1002/1097-0142(19930815)72:4<1224::aid-cncr2820720415>3.0.co;2-b] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND Hyperthermic isolated limb perfusion (HILP) has been shown to be effective for locoregional metastases or local recurrent disease. Locoregional recurrences after previous HILP is an unsolved problem. METHODS HILP with cisplatin, 20-30 mg/l perfused limb volume, was performed in seven patients with recurrent melanoma (five with Stage IIIA and two with Stage IIIAB) after previous HILP with melphalan with or without dactinomycin. A cisplatin perfusion without local excision was performed in four patients; this treatment resulted in two complete responses and one partial response. In three patients, a cisplatin perfusion was performed with local excision of the in-transit metastases. RESULTS During a median follow-up of 20 months (range, 10-25 months), in five (83%) patients the tumor recurred locally after a median period of 5 months (range, 3-11 months). No systemic toxicity was observed. Local toxicity consisted of postperfusion edema and neurotoxicity in all patients. The edema resolved within 2 weeks, which was in contrast to persistent neurotoxicity. A severe motor-sensory neuropathy was observed in three (43%) patients and mild sensory neuropathy in four (57%) patients. CONCLUSIONS The severe neurotoxicity and the high local recurrence rate do not justify the use of HILP with cisplatin for recurrent melanoma after previous HILP with melphalan with or without dactinomycin.
Collapse
Affiliation(s)
- H J Hoekstra
- Department of Surgical Oncology, Groningen University Hospital, The Netherlands
| | | | | | | | | |
Collapse
|
13
|
Fletcher WS, Woltering EA, Moseley HS, Bos G, Lebredo L, Brown D, Small K. Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin. Cancer Treat Res 1993; 62:241-4. [PMID: 8096739 DOI: 10.1007/978-1-4615-3518-8_28] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
14
|
Cavaliere R, Di Filippo F, Giannarelli D, Carlini S, Anzà M, Cavaliere F, Graziano F, Perri P. Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. SEMINARS IN SURGICAL ONCOLOGY 1992; 8:374-80. [PMID: 1439448 DOI: 10.1002/ssu.2980080608] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
On the basis of personal experience and a review of the literature, the authors have evaluated the results obtained with hyperthermic antiblastic perfusion (HAP) for the treatment of stage II, III and IIIAB limb melanoma. The evaluation showed that today HAP may be considered a safe and effective treatment, with a major complication rate ranging between 1% and 4%. In terms of tumor response, locoregional control and survival, this treatment has provided better results than other regional chemotherapeutic modalities and undoubtedly better results than those obtained with conventional, even radical, surgery. The multiparametric analysis showed that, of the treatment-related prognostic factors, the minimum tumor temperature influenced the percentage of complete response (CR) to the greatest extent (P < 0.03), with a positive trend also with regard to the dosage of the antiblastic drug employed (P < 0.08). In turn, the complete response rate was a determinant as far as locoregional control (75.3%; P < 0.0009) and disease-free (51.4%; P < 0.009) and overall survival (63.2%; P < 0.009) rates were concerned. Of the tumor-related prognostic factors, the number of lesions (P < 0.0014), sex (P < 0.04), and the number of disease recurrences (P < 0.01) appear to influence overall survival.
Collapse
Affiliation(s)
- R Cavaliere
- Department of Surgery, Regina Elena Institute for Cancer Research, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16:227-33. [PMID: 1561803 DOI: 10.1007/bf02071525] [Citation(s) in RCA: 103] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In patients with advanced or recurrent melanoma confined to a limb, hyperthermic isolated limb perfusion (ILP) with melphalan produces complete remission in 35-40% of cases and partial remission in a further 35-40%. Mild or moderate limb toxicity is usual, but severe toxic reactions in the limb sometimes occur. After preliminary reports suggested that cisplatin administered by ILP was even more effective than melphalan yet less toxic, a study was undertaken to further assess the value of hyperthermic ILP with cisplatin in the management of limb melanoma. Ten patients were treated. The procedure failed to eliminate melanoma in the limb in 5 of the 6 who received therapeutic ILPs for recurrent disease, and recurrence developed in 2 of the 4 patients who received prophylactic ILPs. Toxicity in the perfused limbs was unacceptably high, with 2 of the 10 patients having severe reactions, one necessitating amputation. We conclude from the results of this study and from a review of literature that neither cisplatin nor any other drug or drug combination so far used for ILP in melanoma patients achieves results which are clearly superior to those achieved with melphalan. Studies are currently in progress investigating double perfusion protocols, new strategies with regional hyperthermia, and the administration by ILP of biological response modifiers such as tumor necrosis factor and interferon. However, for the present, hyperthermic ILP with melphalan remains the treatment most likely to be successful in eliminating or controlling advanced or recurrent melanoma in a limb.
Collapse
Affiliation(s)
- J F Thompson
- Sydney Melanoma Unit, Royal Prince Alfred Hospital, New South Wales, Australia
| | | |
Collapse
|
16
|
Affiliation(s)
- D G Coit
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
| |
Collapse
|
17
|
Meyer JL, Kapp DS, Fessenden P, Hahn GH. Hyperthermic oncology: current biology, physics and clinical results. Pharmacol Ther 1989; 42:251-88. [PMID: 2664823 DOI: 10.1016/0163-7258(89)90038-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- J L Meyer
- Division of Radiation Therapy, Stanford University School of Medicine, California 94305
| | | | | | | |
Collapse
|
18
|
Abstract
Tumor hyperthermia is a rediscovered technique of oncotherapy which has confirmed value in many studies on cell cultures, rodent and mammalian tumors as well as first investigations on patients with tumors. The biological basis for using heat in the treatment of cancer is well established. Various direct and indirect mechanisms are significant for the effect of hyperthermia on tumor tissue. Whereas there are already extensive studies on the direct effects of hyperthermia on DNA, RNA, and protein synthesis, energy metabolism, and the membrane properties of tumor cells, the indirect effects have only been investigated more closely in recent years. These are likewise important for the damage to the tumor tissue and are mediated above all via alterations in the microcirculation and the environment. The recently gained increasing significance of this new technique in combination with other treatment modalities is well documented. Technical problems of heat application must be overcome, especially in deeper tumors and problems of thermometry must be solved in order to be able to apply tumor hyperthermia not only to selected advanced or recurrent tumors, but in order to use it as the fourth pillar of tumor therapy besides surgery, radiotherapy and chemotherapy. This article considers the biological basis and important aspects of hyperthermia therapy in combination with radiotherapy and chemotherapy.
Collapse
Affiliation(s)
- J Otte
- Department of Pediatrics, Childrens Hospital, Medical University, Lübeck, Federal Republic of Germany
| |
Collapse
|
19
|
Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R, Fletcher WS. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988; 155:667-71. [PMID: 3369621 DOI: 10.1016/s0002-9610(88)80140-5] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Fifty-nine patients with melanoma or soft tissue sarcoma of the extremities underwent hyperthermic isolated limb perfusion utilizing cisplatin and wide local excision. Doses of cisplatin ranged from 0.75 to 2 mg/kg. The mortality and morbidity rates were 0 and 6.8 percent, respectively. Pharmacokinetic studies indicate that cisplatin is rapidly bound to perfused tissues and remains bound for 1 month. Maximum tumor response in sarcomas occurs 1 to 2 weeks after perfusion, compared with 1 month after perfusions with l-phenylalanine mustard and actinomycin D. Local and regional recurrence rates were 0 and 3.4 percent, respectively, at 1 year. Further studies of hyperthermic limb perfusions with cisplatin are warranted.
Collapse
Affiliation(s)
- R F Pommier
- Division of Surgical Oncology, Oregon Health Sciences University, Portland 97201
| | | | | | | | | | | |
Collapse
|